Tumor-Infiltrating Lymphocytes in Breast Cancer. Association with Clinical and Pathological Parameters


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

In patients with primary resectable breast cancer, a positive correlation between the age and the count of CD16+ lymphocytes and a negative correlation of this parameter with the number of regulatory CD4+CD25+CD127 cells and proliferative activity of Ki-67 tumor cells were revealed. Higher level of Ki-67 was associated with reduced number of effector lymphocytes (CD8+ and CD16+) and elevated content of regulatory CD8+CD11bCD28 T cells. The absence of expression of estrogen receptors was associated with reduced cytotoxic potential of CD8+ T cell in comparison with ER+ breast cancer. The percentage of CD8+ lymphocytes (CD3+CD8+ and CD8+CD11b+CD28+) among lymphocytes infiltrating the tumor was higher in PR+ breast cancer than in PR tumors. With increasing the tumor load, the number of lymphocytes expressing CD16 marker and their cytotoxic potential decreased.

Sobre autores

T. Zabotina

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Autor responsável pela correspondência
Email: tatzabotina@yandex.ru
Rússia, Moscow

O. Korotkova

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: tatzabotina@yandex.ru
Rússia, Moscow

A. Chertkova

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: tatzabotina@yandex.ru
Rússia, Moscow

E. Zakharova

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: tatzabotina@yandex.ru
Rússia, Moscow

D. Tabakov

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: tatzabotina@yandex.ru
Rússia, Moscow

N. Dzhgamadze

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: tatzabotina@yandex.ru
Rússia, Moscow

M. Savostikova

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: tatzabotina@yandex.ru
Rússia, Moscow

E. Artamonova

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: tatzabotina@yandex.ru
Rússia, Moscow

V. Khailenko

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: tatzabotina@yandex.ru
Rússia, Moscow

E. Kovalenko

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: tatzabotina@yandex.ru
Rússia, Moscow

Z. Kadagidze

N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation

Email: tatzabotina@yandex.ru
Rússia, Moscow


Declaração de direitos autorais © Springer Science+Business Media, LLC, part of Springer Nature, 2018

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies